Mariana Castanheira

Summary

Affiliation: JMI Laboratories
Country: USA

Publications

  1. ncbi Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae
    Mariana Castanheira
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Microb Drug Resist 16:61-5. 2010
  2. ncbi Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp
    Mariana Castanheira
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 63:426-33. 2009
  3. ncbi Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008)
    Mariana Castanheira
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 65:1353-8. 2010
  4. ncbi In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods
    Michael A Pfaller
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 55:5155-8. 2011
  5. ncbi Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009)
    Michael A Pfaller
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 38:65-9. 2011
  6. ncbi Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods
    Mariana Castanheira
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 56:352-7. 2012
  7. ncbi Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009
    Michael A Pfaller
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 55:561-6. 2011
  8. ncbi Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007)
    Mariana Castanheira
    JMI Laboratories, North Liberty, Iowa, USA
    Microb Drug Resist 14:211-6. 2008
  9. ncbi Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 63:55-9. 2009
  10. ncbi First descriptions of blaKPC in Raoultella spp. (R. planticola and R. ornithinolytica): report from the SENTRY Antimicrobial Surveillance Program
    Mariana Castanheira
    JMI Laboratories, North Liberty, Iowa, USA
    J Clin Microbiol 47:4129-30. 2009

Detail Information

Publications43

  1. ncbi Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae
    Mariana Castanheira
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Microb Drug Resist 16:61-5. 2010
    ..The occurrence of KPC-producing and CTX-M-producing isolates has rapidly increased especially in U.S. hospitals, and expanded therapeutic options are needed to treat infections caused by these emerging organisms...
  2. ncbi Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp
    Mariana Castanheira
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 63:426-33. 2009
    ..Given the limited treatment choices available, doripenem appears to offer potency and an enhanced spectrum of activity usable against these troublesome pathogens, particularly against P. aeruginosa...
  3. ncbi Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008)
    Mariana Castanheira
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 65:1353-8. 2010
    ..To determine fusidic acid resistance rates (MICs of > or = 2 mg/L) and the prevalence of fusidic acid resistance mechanisms among Staphylococcus spp. collected from European countries (2008)...
  4. ncbi In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods
    Michael A Pfaller
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 55:5155-8. 2011
    ..terreus SC (MEC, 0.015 μg/ml). In conclusion, E1210 was a very potent and broad-spectrum antifungal agent regardless of in vitro method applied, with excellent activity against AMB-R and itraconazole-R strains of Aspergillus spp...
  5. ncbi Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009)
    Michael A Pfaller
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 38:65-9. 2011
    ..Concern regarding C. glabrata must now include resistance to echinocandins as well as azole antifungal agents...
  6. ncbi Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods
    Mariana Castanheira
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 56:352-7. 2012
    ..and Scedosporium spp. Furthermore, in vitro susceptibility testing of E1210 against isolates of Fusarium and Scedosporium may be accomplished using either of the CLSI or EUCAST BMD methods, each producing very similar results...
  7. ncbi Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009
    Michael A Pfaller
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 55:561-6. 2011
    ..Although resistance to the azoles and echinocandins remains uncommon among CO isolates, we demonstrate the emergence of nosocomial occurrences of C. glabrata expressing resistance to both monitored classes of antifungal agents...
  8. ncbi Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007)
    Mariana Castanheira
    JMI Laboratories, North Liberty, Iowa, USA
    Microb Drug Resist 14:211-6. 2008
    ..S. hospitals participating in the MYSTIC Program in 2007...
  9. ncbi Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 63:55-9. 2009
    ..isolates recovered from medical centres in the Asia-Pacific (APAC) region...
  10. ncbi First descriptions of blaKPC in Raoultella spp. (R. planticola and R. ornithinolytica): report from the SENTRY Antimicrobial Surveillance Program
    Mariana Castanheira
    JMI Laboratories, North Liberty, Iowa, USA
    J Clin Microbiol 47:4129-30. 2009
    ..All patients had received previous antimicrobial treatment, including carbapenems. These strains harbored bla(KPC-2) and bla(KPC-3). Carbapenemase genes were embedded in isoforms of Tn4401 and were plasmidic and chromosomal in location...
  11. ncbi TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 63:716-20. 2009
    ..In this study, single-step mutation frequencies, passaging and the activity of TR-700 were tested against a worldwide collection of linezolid-non-susceptible organisms and matched controls...
  12. ncbi Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008)
    Shawn A Messer
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Clin Microbiol 48:2984-7. 2010
    ..5 microg/ml were further analyzed for potential fks hot spot (HS) mutations; three isolates had confirmed mutations in the fks1 HS1 region (S645P), and three exhibited mutations in the fks2 HS1 region (S645F and S645P)...
  13. ncbi Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates
    David J Farrell
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 35:537-43. 2010
    ....
  14. ncbi Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection
    Douglas J Biedenbach
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 54:4009-11. 2010
    ..03 microg/ml), azithromycin and clarithromycin (MIC(90), 0.12 microg/ml), and erythromycin (MIC(90), 0.25 microg/ml). CEM-101 could provide a potent alternative for the prophylaxis of meningococcal disease...
  15. ncbi CEM-101 activity against Gram-positive organisms
    Leah N Woosley
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 54:2182-7. 2010
    ....
  16. ncbi Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program
    Mariana Castanheira
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 52:570-3. 2008
    ....
  17. ncbi Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida
    Michael A Pfaller
    JMI Laboratories, North Liberty, IA 52317, USA
    J Clin Microbiol 49:3800-4. 2011
    ..2]), and VRC (0.25 [98.2]). In the absence of species-specific CBP values, these WT MIC distributions and ECVs will be useful for monitoring the emergence of reduced susceptibility to the triazole and echinocandin antifungals...
  18. ncbi Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci
    Shannon D Putnam
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 37:39-45. 2011
    ..faecalis (0.25 μg/mL). In summary, solithromycin demonstrated high potency against many Staphylococcus and Enterococcus spp. isolated from contemporary infections worldwide...
  19. ncbi Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009)
    Michael A Pfaller
    JMI Laboratories, 345 Beaver Kreek Centre, North Liberty, Iowa 52317, USA
    J Clin Microbiol 49:396-9. 2011
    ..5%), and C. albicans isolates were more common in APAC (56.9%), with C. parapsilosis (25.6%) and C. tropicalis (17.0%) being more prominent in LAM. Emerging resistance patterns among C. glabrata cases in NAM require focused surveillance...
  20. ncbi Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. isolated in North America and Australia, 2007-2008
    Mariana Castanheira
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 54:3614-7. 2010
    ..In summary, this study shows that acquired genes are highly prevalent among FA-resistant strains (>90%) in three nations with distinct or absence (United States) of fusidic acid clinical use...
  21. ncbi Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18)
    Mariana Castanheira
    JMI Laboratories, North Liberty, Iowa 52317, USA
    Antimicrob Agents Chemother 53:1225-7. 2009
    ..In this study, we show that VIM-producing Pseudomonas spp. were highly prevalent in India with a great diversity of bla(VIM) types and MbetaL-carrying integrons...
  22. ncbi Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types
    Mariana Castanheira
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 56:4779-85. 2012
    ....
  23. ncbi In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010)
    David J Farrell
    JMI Laboratories, North Liberty, Iowa 52317, USA
    Clin Infect Dis 55:S206-14. 2012
    ..1%. Ceftaroline surveillance in the United States during 2008-2010 documented sustained potency and spectrum against multidrug-resistant S. aureus and multidrug-resistant S. pneumoniae known to cause ABSSSI and CABP...
  24. ncbi In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method
    Michael A Pfaller
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 71:167-70. 2011
    ..008-0.06 μg/mL), and was the most potent agent tested against caspofungin-resistant strains of C. albicans (MIC range, 0.008-0.12 μg/mL), C. glabrata (MIC range, 0.03-0.06 μg/mL), and C. tropicalis (MIC range, 0.015-0.06 μg/mL)...
  25. ncbi In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United States
    Ronald N Jones
    JMI Laboratories, North Liberty, Iowa, USA
    Clin Infect Dis 52:S477-86. 2011
    ..Fusidic acid is a promising oral therapy for staphylococcal skin and skin structure infections in the United States, where the contemporary S. aureus population remains without significant resistance...
  26. ncbi Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimi
    Michael A Pfaller
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 69:45-50. 2011
    ..fumigatus. Overall, echinocandin and triazole resistance rates were minimal; however, the distinct increase in echinocandin resistance observed among C. glabrata strains warrants further surveillance associated with molecular support...
  27. ncbi Detection of methyltransferases conferring high-level resistance to aminoglycosides in enterobacteriaceae from Europe, North America, and Latin America
    Thomas R Fritsche
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 52:1843-5. 2008
    ..The global emergence of high-level aminoglycoside resistance has become a rapidly changing event requiring careful monitoring...
  28. ncbi Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009)
    Michael A Pfaller
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 68:278-83. 2010
    ..Cg BSI isolates may show lower susceptibility rates to both azoles and echinocandins with the highest rates of resistance detected in 20- to 59-year-old patients...
  29. ncbi The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009)
    David J Farrell
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Infect 61:476-83. 2010
    ....
  30. ncbi Dissemination and diversity of metallo-beta-lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program
    Helio S Sader
    The JONES Group JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA, USA
    Int J Antimicrob Agents 25:57-61. 2005
    ..The emergence and dissemination of mobile MbetaL-producing isolates represent an alarming factor for increasing resistance to carbapenems in several medical centres evaluated by the SENTRY Program in Latin America...
  31. ncbi Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods
    Michael A Pfaller
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 66:2581-4. 2011
    ..To compare European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI broth microdilution (BMD) methods for testing the novel antifungal E1210 against a recent collection of 102 clinical isolates of Candida spp...
  32. ncbi First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 52:2244-6. 2008
    ..We describe the first detection of cfr-mediated linezolid resistance in Staphylococcus aureus and Staphylococcus epidermidis recovered from human infection cases monitored during the 2007 LEADER Program...
  33. ncbi Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006-2007
    Mariana Castanheira
    JMI Laboratories, North Liberty, Iowa 52317, USA
    Antimicrob Agents Chemother 55:1274-8. 2011
    ..Multiple pulsed-field gel electrophoresis patterns and clonal dissemination within and among sites were observed. Isolates producing NDM-1 were disseminated in Indian health care facilities as early as 2006...
  34. ncbi Characterization of global patterns and the genetics of fusidic acid resistance
    David J Farrell
    JMI Laboratories, North Liberty, Iowa 52317, USA
    Clin Infect Dis 52:S487-92. 2011
    ....
  35. ncbi Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial
    David J Farrell
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 74:73-4. 2012
    ..Overall moxifloxacin and levofloxacin resistance rates were 31.5% and 46.9%, respectively. These favorable results support the continued clinical development of JNJ-Q2 to treat ABSSSI...
  36. ncbi Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006)
    Mariana Castanheira
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 61:235-9. 2008
    ..Resistance to other compounds, such as vancomycin, oxacillin, and penicillin, did not adversely influence daptomycin activity. Daptomycin remains highly active against clinical Gram-positive isolates collected in North America...
  37. ncbi Performance of fusidic acid (CEM-102) susceptibility testing reagents: broth microdilution, disk diffusion, and Etest methods as applied to Staphylococcus aureus
    Ronald N Jones
    JMI Laboratories, North Liberty, Iowa 52317, USA
    J Clin Microbiol 48:972-6. 2010
    ..7% +/- one log2 dilution. The diagnostic susceptibility testing reagents (including Etest) for fusidic acid (CEM-102) performed at an excellent level of intermethod agreement for the proposed breakpoint criteria...
  38. ncbi United States resistance surveillance results for linezolid (LEADER Program for 2007)
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA Tufts University School of Medicine, Boston, MA 02111, USA
    Diagn Microbiol Infect Dis 62:416-26. 2008
    ..aureus and Staphylococcus epidermidis strains from Arizona and Ohio. The LEADER Program appears to be an effective and sensitive surveillance tool to detect novel resistance phenotypes and genotypes...
  39. ncbi CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria
    Shannon D Putnam
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 66:393-401. 2010
    ....
  40. ncbi Candida guilliermondii and other species of candida misidentified as Candida famata: assessment by vitek 2, DNA sequencing analysis, and matrix-assisted laser desorption ionization-time of flight mass spectrometry in two global antifungal surveillance pro
    Mariana Castanheira
    JMI Laboratories, North Liberty, Iowa, USA
    J Clin Microbiol 51:117-24. 2013
    ..famata in fungal infections is much lower than previously appreciated and that commercial systems do not produce accurate identifications except for the newly introduced MALDI-TOF instruments...
  41. ncbi Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme
    Michael A Pfaller
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Mycopathologia 174:259-71. 2012
    ..Molecular confirmation of fungal identification is essential in epidemiological surveys such as SENTRY...
  42. ncbi Evaluation of quinolone resistance-determining region mutations and efflux pump expression in Neisseria meningitidis resistant to fluoroquinolones
    Mariana Castanheira
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 72:263-6. 2012
    ..Alterations in expression of mtrCED pump appear to have minimal influence on ciprofloxacin resistance, and this finding was supported by low rifampin susceptible-level results (MIC, ≤0.008 to 0.03 μg/mL)...
  43. ncbi Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains
    Mariana Castanheira
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 54:2655-9. 2010
    ..Furthermore, results from this large, geographically diverse Candida spp. collection demonstrated that fks1 HS1 mutations remain uncommon among isolates with various echinocandin MIC levels...